AIM:To investigate efficacy of ranibizumab combined with laser treatment for patients with branch retinal vein occlusion(BRVO)and macular edema.

METHODS: We selected 67 patients(67 eyes)with BRVO and macular edema in our hospital from March 2013 to June 2016, they were randomly divided into observation group(n=31)and control group(n=36). The observation group was treated with ranibizumab combined with laser treatment. The control group was treated with macular grid photocoagulation. We observed best corrected visual acuity(BCVA), centre macular thickness(CMT)and macular leakage of two groups.

RESULTS: The BCVA of observation group at 1, 2 and 3mo after treatment were 0.41±0.07, 0.42±0.05 and 0.48±0.05, significantly higher than those of the control group(P<0.05). The CMT of observation group at 1, 2 and 3mo after treatment were 203.11±59.13μm, 201.41±56.22μm and 204.22±60.13μm, significantly lower than those of the control group(P<0.05). The blood vessel leakage of observation group at 3mo after treatment was significantly better than that of the control group(P<0.05). No leakage ratio in the observation group was 71%. There were no postoperative infection, aseptic endophthalmitis and other complications in the two groups.

CONCLUSION: Ranibizumab combined with laser treatment in patients with BRVO and macular edema has better curative effect, can improve the visual acuity of patients, eliminate macular edema, and is safe and reliable.